中国绿岛科技(02023.HK)拟5655万元收购联营公司82%股权
格隆汇 4 月 19日丨中国绿岛科技(02023.HK)发布公告,2020年10月10日,买方(浙江绿岛科技有限公司,公司的间接全资附属公司)与卖方(即台州青唤贸易有限公司)订立收购协议,据此,根据收购协议的条款及条件,卖方已同意出售目标公司(即国药景岳气雾剂有限公司)82%股权,现金代价为人民币5655万元。完成已于签订收购协议时进行。
目标公司为一间于中国成立的有限公司,连同其附属公司主要从事研究及开发、制造及销售医用及食用气雾剂产品项目的投资及开发。紧接收购事项完成前,集团透过买方持有目标公司的7%股权。完成后,目标公司由买方拥有89%权益及由两名独立第三方拥有11%权益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.